Cytocom, Inc.
CBLI · NASDAQ
12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |
|---|---|---|---|---|
| Revenue | $263 | $1,113 | $1,138 | $1,948 |
| % Growth | -76.4% | -2.2% | -41.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $263 | $1,113 | $1,138 | $1,948 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $691 | $1,656 | $3,619 | $5,048 |
| G&A Expenses | $2,158 | $1,818 | $2,319 | $2,501 |
| SG&A Expenses | $2,158 | $1,818 | $2,319 | $2,501 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2,849 | $3,474 | $5,938 | $7,549 |
| Operating Income | -$2,587 | -$2,361 | -$4,800 | -$5,601 |
| % Margin | -983.7% | -212% | -421.7% | -287.5% |
| Other Income/Exp. Net | $337 | -$620 | $1,092 | -$4,242 |
| Pre-Tax Income | -$2,250 | -$2,981 | -$3,707 | -$9,843 |
| Tax Expense | $149 | -$334 | $1,092 | -$4,242 |
| Net Income | -$2,398 | -$2,647 | -$3,612 | -$9,706 |
| % Margin | -912.2% | -237.7% | -317.3% | -498.2% |
| EPS | -0.19 | -0.23 | -0.32 | -0.87 |
| % Growth | 17.4% | 28.1% | 63.2% | – |
| EPS Diluted | -0.19 | -0.23 | -0.32 | -0.87 |
| Weighted Avg Shares Out | 12,397 | 11,298 | 11,294 | 11,192 |
| Weighted Avg Shares Out Dil | 12,397 | 11,298 | 11,294 | 11,192 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $11 | $14 | $18 | $21 |
| EBITDA | -$2,387 | -$2,633 | -$3,594 | -$9,685 |
| % Margin | -907.8% | -236.5% | -315.7% | -497.1% |